Last reviewed · How we verify
Vitamins E + C
Vitamins E and C work as antioxidants to neutralize free radicals and reduce oxidative stress in the body.
Vitamins E and C work as antioxidants to neutralize free radicals and reduce oxidative stress in the body. Used for Nutritional supplementation in hospitalized patients, Antioxidant support in critical care settings.
At a glance
| Generic name | Vitamins E + C |
|---|---|
| Also known as | CellaVie (Ferrosan AS, Denmark) |
| Sponsor | University Hospital, Aker |
| Drug class | Vitamin supplement / Antioxidant combination |
| Modality | Small molecule |
| Therapeutic area | Nutritional support / General health |
| Phase | FDA-approved |
Mechanism of action
Vitamin E is a lipid-soluble antioxidant that protects cell membranes from oxidative damage, while vitamin C is a water-soluble antioxidant that supports immune function and collagen synthesis. Together, they help prevent cellular damage from reactive oxygen species and may support overall health and recovery in hospitalized patients.
Approved indications
- Nutritional supplementation in hospitalized patients
- Antioxidant support in critical care settings
Common side effects
- Gastrointestinal upset
- Headache
- Fatigue
Key clinical trials
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (NA)
- A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (NA)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamins E + C CI brief — competitive landscape report
- Vitamins E + C updates RSS · CI watch RSS
- University Hospital, Aker portfolio CI